knowledge -WSS

knowledge

author：knowledge 2025-09-30 12:16:49 - browse：4

Investment bank Goldman Sachs is jumping into the biotech world after raising $650 million to invest in privately held startups.

The bank announced Wednesday that it has closed its first-ever life sciences fund, called West Street Life Sciences I. The plan is to invest the money in genetic medicine, cell therapies, immunotherapies, synthetic biology and artificial intelligence startups, as well as diagnostics and life science tools companies.

First-time funds have been difficult to raise during the biotech downturn. Last year, around $11.6 billion was raised by 183 new VC funds, which was the lowest fundraising total for first-timers since 2013, according to Pitchbook. Around $25.6 billion had been raised by 556 first-time funds in 2022.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Hepatitis C has a cure — but many Americans still lack access to it
Next article： Flu vaccine reformulation won't be easy, manufacturers warn

hotspot

WSS

Carbon Health diabetes program, a test of data

TikTok, Instagram influencers need more rules for drug ads

Medical school prerequisites are outdated

The inclusion problem at the heart of rehabilitation research

Healthy food access boosts outcomes in two studies

After decades in use, heart stents finally beat placebo

knowledge

knowledge

hotspot

What does generative AI mean for health care? We asked experts

Medicare bonuses could stop drug shortages under Senate plan

Apple is now the first public company to be valued at $3 trillion

Prior authorization reform is both possible and imperative

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

HPV vaccine, cervical cancer study delivers historic results

Medicare details structure of new drug price negotiation program

TikTok, Instagram influencers need more rules for drug ads

Heart attack and stroke risk calculators need revising

UnitedHealth sued over use of algorithm in Medicare Advantage plans

hotspot

Ventyx halts psoriasis drug development after lackluster trial results

After decades in use, heart stents finally beat placebo

Carbon Health diabetes program, a test of data

Ventyx halts psoriasis drug development after lackluster trial results

Medicare bonuses could stop drug shortages under Senate plan

Maisha Meds is a PBM, but don't call it that

knowledge

hotspot

hotspot

explore